Cite
HARVARD Citation
Martin-Liberal, J. et al. (n.d.). 143PTumor infiltrating lymphocytes (TILs) and PDL1 expression as prescreening enrichment biomarkers of clinical benefit to immune checkpoint inhibitors (CI) in early clinical trials (ECT). Annals of oncology. p. . [Online].